We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+5.25%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$358M
AUM Growth
+$34.6M
Cap. Flow
+$36.2M
Cap. Flow %
10.1%
Top 10 Hldgs %
49.91%
Holding
70
New
7
Increased
17
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$18.4M
2
HRMY icon
Harmony Biosciences
HRMY
+$13.9M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$9.9M
4
VERA icon
Vera Therapeutics
VERA
+$5.57M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$5.45M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$35.8M
2
TVTX icon
Travere Therapeutics
TVTX
+$5.06M
3
ILMN icon
Illumina
ILMN
+$4.21M
4
QURE icon
uniQure
QURE
+$3.21M
5
DYN icon
Dyne Therapeutics
DYN
+$2.69M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
2 Miscellaneous 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
$40.5M 11.3%
200,200
+34,000
+20% +$5.45M
AMGN icon
2
Amgen
AMGN
$236B
$22.1M 6.15%
91,246
+75,000
+462% +$18.4M
INCY icon
3
Incyte
INCY
$25.9B
$20.2M 5.63%
279,000
+50,000
+22% +$3.91M
HRMY icon
4
Harmony Biosciences
HRMY
$2.32B
$18.6M 5.2%
570,500
+306,000
+116% +$13.9M
ALKS icon
5
Alkermes
ALKS
$8.2B
$16.7M 4.66%
593,000
– –
SUPN icon
6
Supernus Pharmaceuticals
SUPN
$2.57B
$15.3M 4.28%
423,500
+40,000
+10% +$1.54M
ITCI
7
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$14M 3.89%
257,856
+36,000
+16% +$1.74M
RARE icon
8
Ultragenyx Pharmaceutical
RARE
$2.59B
$10.6M 2.95%
264,052
+90,000
+52% +$3.86M
EXEL icon
9
Exelixis
EXEL
$13.7B
$10.5M 2.94%
543,000
– –
VRTX icon
10
Vertex Pharmaceuticals
VRTX
$139B
$10.4M 2.9%
+33,000
New +$9.9M
QURE icon
11
uniQure
QURE
$3.44B
$9.64M 2.69%
478,500
-153,000
-24% -$3.21M
ALNY icon
12
Alnylam Pharmaceuticals
ALNY
$31.7B
$9.33M 2.6%
46,600
+8,600
+23% +$1.81M
REGN icon
13
Regeneron Pharmaceuticals
REGN
$83.1B
$9.2M 2.57%
11,200
– –
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$9.07M 2.53%
244,000
– –
SNY icon
15
Sanofi
SNY
$107B
$7.81M 2.18%
143,500
– –
VERA icon
16
Vera Therapeutics
VERA
$2.5B
$7.75M 2.16%
1,002,257
+721,000
+256% +$5.57M
KDNY
17
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$7.41M 2.07%
319,989
-20,400
-6% -$486K
UTHR icon
18
United Therapeutics
UTHR
$22.7B
$6.38M 1.78%
28,500
+13,500
+90% +$3.33M
AUPH icon
19
Aurinia Pharmaceuticals
AUPH
$2.19B
$6.28M 1.75%
573,530
– –
ILMN icon
20
Illumina
ILMN
$34.4B
$6.16M 1.72%
27,242
-20,560
-43% -$4.21M
BIIB icon
21
Biogen
BIIB
$32.7B
$5.95M 1.66%
21,400
– –
RVNC
22
DELISTED
Revance Therapeutics, Inc.
RVNC
$5.89M 1.64%
183,000
+63,000
+53% +$1.96M
BMRN icon
23
BioMarin Pharmaceuticals
BMRN
$12.6B
$5.7M 1.59%
58,656
+15,000
+34% +$1.56M
DYN icon
24
Dyne Therapeutics
DYN
$4.88B
$4.99M 1.39%
433,751
-207,317
-32% -$2.69M
ONC
25
BeOne Medicines Ltd
ONC
$42.1B
$4.89M 1.37%
22,700
+7,000
+45% +$1.68M
1
2 3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q1 2023 Portfolio in Review

As of Q1 2023, International Biotechnology Trust held 70 positions worth $358M, up 11% from $324M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

International Biotechnology Trust deployed $36.2M of net new capital in Q1 2023, opening 7 new positions and adding to 17 existing holdings. Its largest new stake was Vertex Pharmaceuticals: 33,000 shares worth $10.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Travere Therapeutics, an estimated $5.06M trimmed.

  • International Biotechnology Trust's largest Q1 2023 buy was Vertex Pharmaceuticals: 33,000 shares worth $10.4M.
  • International Biotechnology Trust added most to Amgen in Q1 2023, an estimated $18.4M increase.
  • International Biotechnology Trust's biggest Q1 2023 reduction was Travere Therapeutics, cutting an estimated $5.06M.
  • International Biotechnology Trust fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023, selling an estimated $35.8M.
  • International Biotechnology Trust's ten largest holdings make up 50% of its $358M portfolio in Q1 2023.
  • International Biotechnology Trust opened 7 new positions and closed 6 in Q1 2023.
  • International Biotechnology Trust's portfolio value rose 11% quarter-over-quarter to $358M.

Based on International Biotechnology Trust's 13F filing for Q1 2023, filed 18 May 2023.